Published in Blood Weekly, May 17th, 2001
Even so, according to Francoise Degos and coauthors of the multicenter, collaborative study, HCV patients on hemodialysis who can complete 12 months of treatment may benefit from interferon therapy.
Initially, researchers planned to enroll into the study 120 hemodialysis patients with confirmed evidence of viral infection. "After 37 patients had been included, the study was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.